B
Barbara Haber
Researcher at Merck & Co.
Publications - 114
Citations - 4795
Barbara Haber is an academic researcher from Merck & Co.. The author has contributed to research in topics: Elbasvir & Elbasvir, Grazoprevir. The author has an hindex of 38, co-authored 106 publications receiving 4412 citations. Previous affiliations of Barbara Haber include University of Pennsylvania & Children's Hospital of Philadelphia.
Papers
More filters
Journal ArticleDOI
A multicenter study of the outcome of biliary atresia in the United States, 1997 to 2000.
Benjamin L. Shneider,Morton B. Brown,Barbara Haber,Peter F. Whitington,Kathleen B. Schwarz,Robert H. Squires,Jorge A. Bezerra,Ross W. Shepherd,Philip J. Rosenthal,Jay H. Hoofnagle,Ronald J. Sokol +10 more
TL;DR: Efforts to improve bile flow after HPE may lead to improved outcome in children with biliary atresia, and total bilirubin in early follow-up after HPe was highly predictive of outcome.
Journal ArticleDOI
Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial
Eric Lawitz,Edward Gane,Brian L. Pearlman,Edward Tam,Wayne Ghesquiere,Dominique Guyader,Laurent Alric,Jean-Pierre Bronowicki,Laura Lester,William Sievert,Reem Ghalib,Luis A. Balart,Fredrik Sund,Martin Lagging,Frank J. Dutko,Melissa Shaughnessy,Peggy Hwang,Anita Y. M. Howe,Janice Wahl,Michael N. Robertson,Eliav Barr,Barbara Haber +21 more
TL;DR: The C-WORTHY trial as mentioned in this paper was a randomized, open-label phase 2 trial of grazoprevir plus elbasvir with or without ribavirin in patients with hepatitis C virus (HCV) genotype 1 infection with baseline characteristics of poor response.
Journal ArticleDOI
Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial
Mark S. Sulkowski,Christophe Hézode,Jan Gerstoft,John M. Vierling,Josep Mallolas,Stanislas Pol,Marcelo Kugelmas,Abel Murillo,Nina Weis,Ronald Nahass,Oren Shibolet,Lawrence Serfaty,Marc Bourlière,Edwin DeJesus,Eli Zuckerman,Frank J. Dutko,Melissa Shaughnessy,Peggy Hwang,Anita Y. M. Howe,Janice Wahl,Michael N. Robertson,Eliav Barr,Barbara Haber +22 more
TL;DR: The C-WORTHY trial as mentioned in this paper evaluated the efficacy and safety of a combination of grazoprevir plus elbasvir with or without ribavirin in patients with hepatitis C virus (HCV) mono-infection and co-infected patients.
Journal ArticleDOI
Rapid activation of post-hepatectomy factor/nuclear factor kappa B in hepatocytes, a primary response in the regenerating liver.
TL;DR: It is found that PHF is rapidly activated and turned over in the regenerating liver, demonstrating peak activity at 30 min post-hepatectomy and virtual disappearance by 1 h, and suggests a mechanism by which hepatocytes regulate their mitogenic program during liver regeneration.
Journal ArticleDOI
Induction patterns of 70 genes during nine days after hepatectomy define the temporal course of liver regeneration.
TL;DR: The expression of > 70 genes in clinical settings that could induce liver regeneration, including after perfusion in a donor liver, hepatic ischemia, and fulminant hepatic failure are examined, finding that a small number of early and liver-specific genes were selectively activated in human livers under these conditions.